GLP-1 medicines and pancreatitis: the honest, rare-but-serious risk

If you are on a GLP-1 medicine for weight loss or diabetes, semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), or tirzepatide (Mounjaro, Zepbound), you may have heard a scary word: pancreatitis. That means inflammation of the pancreas, the organ behind your stomach that helps with digestion and blood sugar. The honest picture is the one your doctor and the label give you: pancreatitis is a real, listed warning on GLP-1 medicines, and it can be serious, but it is rare. The labels say acute pancreatitis, including fatal, hemorrhagic or necrotising cases, has been observed in patients treated with GLP-1 receptor agonists, and they tell you to stop the medicine if pancreatitis is suspected. A 2024 meta-analysis of 62 studies and 66,232 patients found a modestly increased relative risk of about 1.44. This guide is for an Indian reader trying to understand the real risk without either ignoring it or panicking. Please talk to your doctor about your own case before any decision.